Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

BCR::ABL1 -Induced Mitochondrial Morphological Changes As a Novel Biomarker for the Artificial Intelligence-Driven Flow Cytometric Detection of Chronic Myeloid Leukemia Cells

Kohjin Suzuki, Naoki Watanabe, Satoru Torii, Tadaaki Inano, Shintaro Kinoshita, Kazuhiro Yamada, Norio Komatsu, Shigeomi Shimizu, Miki Ando, Tomoiku Takaku

Blood (2024) 144 (Supplement 1): 6566.

https://doi.org/10.1182/blood-2024-199940

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2023-180561

Published: 2023

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Blood (2022) 140 (Supplement 1): 12162–12164.

https://doi.org/10.1182/blood-2022-162516

Published: 2022

Journal Articles

Prognostic Factors of Idiopathic Hypereosinophilic Syndrome: A Nationwide Survey in Japan

Akira Honda, Kazuhiro Toyama, Yu Oyama, Kensuke Matsuda, Hideaki Mizuno, Akiko M Saito, Yoshio Katayama, Norio Komatsu, Mineo Kurokawa

Blood (2021) 138 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2021-147609

Published: 2021

Journal Articles

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ruben A. Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2021-147417

Published: 2021

Journal Articles

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Keita Kirito, MD, Kazuya Shimoda, MD PhD, Katsuto Takenaka, MD PhD, Albert Qin, MD PhD, Oleh Zagrijtschuk, MD, Toshiaki Sato, MD PhD, Narihisa Miyachi, Hiroaki Kawase, Katsuya Yonezu, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142504

Published: 2020

Journal Articles

Use of Ppmx-T003 As a Potent Inhibitor of Erythrocytosis in Polycythemia Vera

Nami Masubuchi, PhD, Marito Araki, PhD, Kaho Shioiri, Sota Kitazawa, Yoshihiko Kihara, Yuta Ohira, Fumiko Nomura, Tadashi Matsuura, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-138387

Published: 2020

Journal Articles

MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Daisuke Watanabe, MD, PhD, Hiroki Akiyama, MD, PhD, Kouhei Yamamoto, Takeo Fujiwara, MD, Emiko Sakaida, MDPhD, Yoko Edahiro, MD PhD, Misa Imai, PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Norihiko Kawamata, MD, PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139162

Published: 2020

Journal Articles

Concomitant Occurrence of Polyclonal Hematopoiesis and Cell-Autonomous Megakaryopoiesis in Triple-Negative Essential Thrombocythemia

Tadaaki Inano, MDPhD, Marito Araki, PhD, Soji Morishita, PhD, Misa Imai, PhD, Yoshihiko Kihara, Maho Okuda, PhD, Masafumi Ito, MD PhD, Satoshi Osaga, Yinjie Yang, PhD, Yoko Edahiro, MD PhD, Tomonori Ochiai, MDPhD, Kyohei Misawa, MDPhD, Yasutaka Fukuda, MDPhD, Akimichi Ohsaka, MD PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134494

Published: 2020

Journal Articles

CREB3L1 Overexpression Can Reliably Discriminate Ph-MPNs from Reactive Cases

Soji Morishita, PhD, Hajime Yasuda, MD PhD, Saya Yamawaki, Hideya Kawaji, PhD, Masayoshi Itoh, PhD, Yoko Edahiro, MD PhD, Misa Imai, PhD, Yasushi Kogo, PhD, Satoshi Tsuneda, PhD, Akimichi Ohsaka, MD PhD, Yoshihide Hayashizaki, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-137325

Published: 2020

Journal Articles

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

Hirohiko Shibayama, MD PhD, Hirokazu Tanaka, MD PhD, Su-Peng Yeh, MD, Hui-Hua Hsiao, MD, Silpa Nuthalapati, PhD, Kota Ono, PhD, Kotaro Uehara, MS, Sumiko Okubo, MD PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137068

Published: 2020

Journal Articles

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138953

Published: 2020

Journal Articles

Therapeutic Potential of an Antibody Targeting the Cleaved Form of Mutant Calreticulin in Myeloproliferative Neoplasms

Yoshihiko Kihara, Marito Araki, PhD, Misa Imai, PhD, Yosuke Mori, MD, Mei Horino, Satoko Ogata, PhD, Syunpei Yoshikawa, Teppei Taguchi, Nami Masubuchi, PhD, Yo Mabuchi, PhD, Yinjie Yang, PhD, Yasutaka Fukuda, MDPhD, Soji Morishita, PhD, Takehiro Suzuki, PhD, Naoshi Domae, PhD, Motoyuki Shimonaka, PhD, Chihiro Akazawa, MD PhD, Akimichi Ohsaka, MD PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141159

Published: 2020

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

Blood (2019) 134 (Supplement_1): 4197.

https://doi.org/10.1182/blood-2019-125525

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

Journal Articles

Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2 V617F provide a therapeutic target of elotuzumab

Blood (2019) 134 (10): 814–825.

https://doi.org/10.1182/blood.2019000051

Published: 2019

Includes: Supplemental data

NARROW

BCR::ABL1 -Induced Mitochondrial Morphological Changes As a Novel Biomarker for the Artificial Intelligence-Driven Flow Cytometric Detection of Chronic Myeloid Leukemia Cells

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Prognostic Factors of Idiopathic Hypereosinophilic Syndrome: A Nationwide Survey in Japan

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply

Use of Ppmx-T003 As a Potent Inhibitor of Erythrocytosis in Polycythemia Vera

MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations

Concomitant Occurrence of Polyclonal Hematopoiesis and Cell-Autonomous Megakaryopoiesis in Triple-Negative Essential Thrombocythemia

CREB3L1 Overexpression Can Reliably Discriminate Ph-MPNs from Reactive Cases

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Therapeutic Potential of an Antibody Targeting the Cleaved Form of Mutant Calreticulin in Myeloproliferative Neoplasms

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2 V617F provide a therapeutic target of elotuzumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only